The Sweat Problem
Imagine getting ready for a big meeting. You put on a fresh shirt. But an hour later, you’re sweating through your clothes. It’s not hot outside. You’re not exercising. But your underarms are soaked.
This is the daily reality for millions of people with primary axillary hyperhidrosis. It’s a condition where the body sweats far more than needed to cool down. It affects about 3% of adults worldwide. It can ruin clothes, cause embarrassment, and hurt social confidence.
Current treatments include strong antiperspirants. But for many, these don’t work well. Oral medicines can help but often cause side effects like dry mouth. Surgery is an option, but it’s invasive and can cause other problems. Patients need better, safer solutions.
A New Option for a Stubborn Problem
For years, doctors have used botulinum toxin type A (BoNTA)—the same drug in Botox—to treat excessive sweating. It works by blocking the nerves that trigger sweat glands. But most studies focused on Western populations.
Researchers wanted to know: Does it work the same for Chinese patients? Is it safe? How long does the effect last?
This new Phase 3 study aimed to answer those questions. It’s the first large, rigorous trial specifically for Chinese patients with this condition.
One Shot vs. Placebo
Here’s the twist: This wasn’t a small test. It was a major clinical trial with 344 patients. They were randomly split into two groups. One group got the real BoNTA injection. The other got a placebo—a shot that contained no active drug. Neither the patients nor the doctors knew who got which until the study ended.
The treatment was simple: a single series of tiny injections under the skin of each armpit. The dose was 50 units per armpit. That’s it. No daily pills. No surgery.
How It Calms the Sweat Glands
Think of your sweat glands like a light switch. Normally, your nervous system flips the switch on when your body temperature rises. In hyperhidrosis, the switch is stuck in the “on” position.
BoNTA acts like a temporary dimmer switch. It doesn’t break the switch. Instead, it blocks the signal that tells the glands to produce sweat. The glands themselves stay healthy. The effect wears off slowly as the body naturally breaks down the toxin. This is why the treatment isn’t permanent, but it lasts for months.
The Study Snapshot
The trial took place across multiple centers in China. Patients were followed for 16 weeks after their single injection. The main goal was to see if their underarm sweat weight dropped by at least 50% compared to their starting point. Researchers also tracked sweat area, disease severity scores, and patient satisfaction.
The results were clear and significant.
At Week 4, 83.7% of patients who got the real BoNTA injection saw their sweat weight drop by more than half. In the placebo group, only 55.8% saw that kind of reduction.
That’s a difference of nearly 28 percentage points. The result was statistically significant, meaning it’s very unlikely to be due to chance.
But the benefits didn’t stop there. The sweat reduction started quickly—within one week—and stayed strong through Week 16. That’s four full months of relief from a single treatment.
Patients also reported major improvements in their quality of life. Their scores on the Hyperhidrosis Disease Severity Scale (HDSS) went down. This scale measures how much sweating interferes with daily activities. A lower score means less interference.
They also felt better about how they smelled. The study measured bromhidrosis, which is body odor caused by sweat breaking down on the skin. The BoNTA group saw a significant drop in odor grades.
And perhaps most telling: patient satisfaction scores were much higher in the BoNTA group compared to the placebo group.
This doesn’t mean this treatment is available yet.
A Safe Profile
Safety was a top concern. The good news? BoNTA was well tolerated. Most side effects were mild and temporary, like slight pain or bruising at the injection site.
No one in either group had a serious adverse reaction. No one dropped out of the study because of side effects. No deaths were reported. This suggests the treatment is safe for Chinese patients, at least in the short term.
While this study focused on Chinese patients, the results align with global data. BoNTA is already approved for hyperhidrosis in many countries. This research adds a key piece of evidence for a specific population. It confirms that the treatment works similarly across ethnic groups. For doctors, this means they can confidently offer this option to their Chinese patients.
If you struggle with excessive underarm sweating, this is promising news. BoNTA injections are already available in many clinics worldwide. However, this specific 50-unit dose and protocol may need regulatory approval in China before it becomes standard practice.
Talk to a dermatologist or a doctor specializing in hyperhidrosis. They can assess if you’re a candidate. Remember, this is a prescription treatment. It’s not a one-size-fits-all solution.
This study has some limits. It only looked at Chinese patients, so results may not apply to everyone. The follow-up was 16 weeks; longer studies are needed to see how long the effect truly lasts. Also, the study only tested one dose. Different doses might work better for some people.
What’s next? Researchers will likely continue to monitor patients for longer-term effects. They may also explore if repeated treatments remain safe and effective over years. For now, this study provides strong evidence that a single BoNTA injection can safely and effectively reduce underarm sweating for months in Chinese patients. It’s a solid step forward for a condition that affects daily life more than many realize.
